$21.08
−1.03%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$21.65
From 52W high−61.72%
Volume44752.00
Market cap$1.07B
P/E (TTM)—
P/S (TTM)111.8x
Div yield—
Key dataOct 19, 2026
Open
$21.65
From 52W high
−61.72%
Volume
44752.00
Market cap
$1.07B
ValuationView details →
P/E (Fwd)
128.5x
EV/EBITDA
−29.0x
P/E (TTM)
—
RSI (14)
24.1
MomentumView details →
1D Return
−1.03%
YTD Return
−9.52%
SummaryUpdated Jun 1, 2026
Nanobiotix S.A. (NASDAQ:NBTX) is a clinical-stage biotechnology company founded in 2003 and headquartered in Paris, France. The company went public on NASDAQ in December 2020. Nanobiotix specializes in developing nanotechnology-based therapeutic solutions for cancer treatment, with its lead product candidate NBTXR3 currently in advanced clinical trials. The company has established significant partnerships, most notably a global licensing agreement with Johnson & Johnson worth potentially over $2.5 billion, marking a major validation of its nanotechnology platform approach to oncology.
Similar companies
Latest newsMore news →